Gabriela R. Barredo-Vacchelli

Gabriela R. Barredo-Vacchelli

Auto-generated profile, based on publicly available information

Gabriela R. Barredo-Vacchelli

Facultad de Farmacia y Bioquímica, Cátedra de Biotecnología Universidad de Buenos Aires Ciudad Autónoma de Buenos Aires Argentina

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2024 in Peptide Science
Verified
Journal Article
Closed access
GBGabriela R. Barredo‐Vacchelli
Gabriela R. Barredo‐Vacchelli
JRJésica Ayelén Rodríguez
Jésica Ayelén Rodríguez
JEJoaquin A. Eloy
Joaquin A. Eloy
Silvia Andrea CamperiSilvia Andrea Camperi
Silvia Andrea Camperi

18 February 2023 in International Journal of Peptide Research and Therapeutics
Verified
Journal Article
Closed access
PDF file
JRJésica Ayelén Rodríguez
Jésica Ayelén Rodríguez
GBGabriela R. Barredo-Vacchelli
Gabriela R. Barredo-Vacchelli
LILucía C. Iglesias-García
Lucía C. Iglesias-García
ABAriadna M. Birocco
Ariadna M. Birocco
ABAgustín Blachman
Agustín Blachman
Silvia Andrea CamperiSilvia Andrea Camperi
Silvia Andrea Camperi

3 April 2024
Verified
Journal Article
Open access
PDF file
JRJésica Ayelén Rodríguez
Jésica Ayelén Rodríguez
GBGabriela R. Barredo-Vacchelli
Gabriela R. Barredo-Vacchelli
JEJoaquin A. Eloy
Joaquin A. Eloy
Silvia Andrea CamperiSilvia Andrea Camperi
Silvia Andrea Camperi
Envenomation caused by snakes, scorpions, and spiders represents a serious public health problem in Latin America. The antivenoms used for its treatment are produced by immunizing horses repeatedly with sublethal doses of animal venoms along with the adjuvant. However, venom availability is a bottleneck. Furthermore, toxin-neutralizing antibodies are only a few of the total produced with this classical method. Therefore, high doses of antivenom are required to achieve the neutralization power, which usually causes adverse reactions in the patient. With the aim of obtaining a higher proportion of toxin-neutralizing antibodies while reducing the dependency on venom availability, alternative immunization protocols have been explored using synthetic peptides with epitopes from clinically relevant toxins. The process to design an immunogenic peptide entitles: (a) choice of the medical relevant toxins in the venom; (b) identification of the epitopes in the selected toxins; (c) improvement of peptide immunogenicity; (d) immunogen synthesis; and e) in vitro and in vivo evaluation. The present article aims to review the advances in the design of immunogenic synthetic peptides for their application in antivenom production in Latin America during the 21st century. Epitopes have been identified from many clinically important toxins in Latin American snakes (snake venom metalloproteinases, snake venom serine proteases, crotamine, phospholipases A2, and three-finger toxins), scorpions (beta-mammal/insect toxin Ts1, alpha-mammal toxin Ts2, alpha-mammal toxin Ts3, toxin Ts4, and beta-mammal Tt1g neurotoxin), and spiders (dermonecrotic toxin and delta-ctenitoxin-Pn2a). Nevertheless, their application is still experimental, even though they are ideal for large-scale and low-cost antivenom production, factors that are necessary to meet national and regional demands.